Genmab

	4/11 18:26 af GeorgeBest	Sounds new E L
	4/11 18:26 af E L	it is in trial for Metastatic Castration-Resistant Prostate Cancer (link)
	4/11 18:25 af E L	Is this one new? JNJ-70218902 • Phase 1 study in advanced stage solid tumors ongoing • Developed by Janssen under the DuoBody technology collaboration / JNJ-70218902 is a bispecific antibody created by Janssen using Genmab's DuoBody technology. It is being investigated in a Phase 1 clinical study for the treatment of advanced stage solid tumors. Third Quarter 2020 Update • September: A Phase 1 study of JNJ-70218902 in patients with advanced solid tumors was initiated.
	4/11 18:21 af Helge Larsen/PI-redaktør	Rapporten: (link)
	4/11 18:19 af Helge Larsen/PI-redaktør	(link)
	4/11 18:16 af AaBforever	Genmab overgår forventninger i tredje kvartal/Børsen
	4/11 18:06 af nohope	Spørger bare for at sige noget, skal ikke bruges til noget nyttigt.
	4/11 18:05 af Helge Larsen/PI-redaktør	Det tager kun få sekunder. :-)
	4/11 18:05 af nohope	Er det den største daglige stigning i kroner/point ?
	4/11 18:04 af Helge Larsen/PI-redaktør	Mens vi venter: Meld dig til Q&A med Genmab: (link)
	4/11 18:03 af nohope	Aha - Trump modellen - vi stopper med at tælle når jeg fører....
	4/11 18:01 af nohope	Nu er NBI jo ikke lukket endnu-
	4/11 18:00 af AaBforever	2347
	4/11 18:00 af Stroka	Det lugter af brændte shorts i dag. :-)
	4/11 17:57 af Helge Larsen/PI-redaktør	NBI: (link)
	4/11 17:56 af Helge Larsen/PI-redaktør	Slutauktionen er ikke forbi endnu. ;-)
	4/11 17:53 af nohope	Bortset fra det, så er en stigning på 7 % vel ikke imponerende - når NBI stiger 6 %
	4/11 17:53 af nohope	Trtump har sikkert for travlt til at kigge med i dag...
	4/11 17:52 af Helge Larsen/PI-redaktør	Nu er Italien også med. Vi mangler vores sædvanlige besøgende fra USA.
	4/11 17:50 af Helge Larsen/PI-redaktør	Godt vi fik installeret nye stærke servere i forsommeren. :-)
	4/11 17:47 af Helge Larsen/PI-redaktør	Besøgende i chatten lige nu: 1. Denmark 279 2. Luxembourg 2 3. Germany 1 4. Netherlands 11 5. Norway 1 6. Sweden 1 7. Turkey 1 8. United Arab Emirates
	4/11 17:41 af StockBull	AbbVie +9% - kanon dag
	4/11 17:28 af E L	i can't find that one online yet?
	4/11 17:22 af E L	Subcutaneous Epcoritamab Induces Complete Responses With an Encouraging Safety Profile Across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients With Prior CAR-T Therapy: Updated Dose-Escalation Data– Oral presentation,

	4/11 17:21 af E L	Genmab Announces Data to be Presented at 2020 ASH Annual Meeting (link)
	4/11 17:18 af AaBforever	Gen 6%...:-)
	4/11 17:01 af Solsen	Knock off your socks ;-)
	4/11 15:54 af Bulder	indeed, can't wait to see the outcome in combo with dara.
	4/11 15:50 af E L	looks good though, no?
	4/11 15:50 af E L	ORR was a bit higher at IV though, probably still have to jack up the SC dose a bit
	4/11 15:49 af E L	that is a good point. the PhII is also SC (link)
	4/11 15:42 af Bulder	(link)
	4/11 15:41 af Bulder	Yes, but only grade 1-2 with sc dosing. Amd it looks that they have decided for sc, as that is the chosen adm in the combination study.
	4/11 15:33 af E L	MTD has not been defined and dose escalation continues, with the study nearing a RP2D.
	4/11 15:33 af E L	very interesting. had Talquetamab as a lotery ticket, early data encouriging though, even though a few grade 3 crs ?
	4/11 15:07 af E L	A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) (link)
	4/11 14:55 af E L	Pattern of Use and Efficacy of Daratumumab-Based Therapy in Patients with AL Amyloidosis: A Single Institution Experience
	4/11 14:53 af E L	i just picked 1 Dara abstract, too many to post all
	4/11 14:27 af E L	forget that last one, it is old offcourse
	4/11 14:24 af E L	Immunoprofiling of Normal Human Donor Blood Identified Potential Pharmacodynamic Markers for JNJ-63709178 (CD123xCD3) Duobody® Antibody Treatment (link)
	4/11 14:21 af E L	Duobody-CD3xCD20 Shows Unique and Potent Preclinical Anti-Tumor Activity in Vitro and In Vivo, and Is Being Evaluated Clinically in Patients with B-Cell Malignancies (link)
	4/11 14:20 af E L	First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody®-CD3×CD20) in B-Cell Non-Hodgkin Lymphomas (link)
	4/11 14:20 af E L	GEN3013 - Duobody-CD3xCD20 Induces Potent Anti-Tumor Activity in Malignant Lymph Node B Cells from Patients with DLBCL, FL and MCL Ex Vivo, Irrespective of Prior Treatment with CD20 Monoclonal Antibodies (link)
	4/11 14:12 af E L	Preclinical Anti-Tumor Activity of Hexabody-CD38 in Patient-Derived B Cell Lymphoma and Acute Myeloid Leukemia Xenograft Models (link)
	4/11 14:08 af E L	Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM) (link)
	4/11 11:24 af Sukkeralf	(link)
	4/11 11:24 af Sukkeralf	Analytikere øjner opjustering:
	4/11 11:23 af Sukkeralf	Set i lyset af at der kommer stort fokus på BsAbs i ved Genmabs CMD, så kunne det jo ligeledes give større og større håb for Genmabs måske førende position indenfor dette område
	4/11 11:22 af Sukkeralf	Skorney noted that the validation provided by these two bispecifics could give a boost to the rest of Regeneron’s portfolio, and “should help support a long-term pipeline thesis.”
	4/11 11:22 af Sukkeralf	The most advanced candidate in the portfolio is REGN1979, a CD20/CD3-targeting antibody that made a bit of a splash last year with preliminary human data in non-Hodgkin’s lymphoma (NHL). Regeneron also has a BCMA/CD3 agent that is expected to generate initial efficacy results in multiple myeloma (MM), and a handful of even earlier stage candidates in Phase I testing.